Physician profile
Jayaraman Ravindran
NPI 1497719348
$4,823.89
in general payments reported to CMS, 2019-2025
41 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $526 · 2021: $1,021 · 2022: $407 · 2023: $573 · 2024: $483 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $669.49 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $592.46 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Biogen, INC. | $424.95 | 2019-2025 | Vumerity, Skyclarys, Avonex |
| Abbvie INC. | $415.77 | 2021-2025 | |
| Ucb, INC. | $338.95 | 2019-2025 | Fintepla, Briviact |
| Medtronic, INC. | $226.52 | 2022-2025 | Percept PC Brainsense |
| Emd Serono, INC. | $189.86 | 2019-2021 | |
| Lundbeck LLC | $158.44 | 2020-2025 | Vyepti |
| Genzyme Corporation | $149.01 | 2019-2021 | |
| Eisai INC. | $134.63 | 2020-2025 | |
| Penumbra, INC. | $121.46 | 2019 | |
| Lilly USA, LLC | $119.11 | 2019-2025 | Amyvid, Kisunla |
| Acadia Pharmaceuticals INC | $108.30 | 2019-2025 | Nuplazid |
| Acorda Therapeutics, INC | $102.80 | 2019-2023 | Inbrija |
| Allergan, INC. | $102.45 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayaraman Ravindran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.